J&J’s Mylanta, Mylicon Lines Return Via ‘Fixed-Term’ License With Infirst
This article was originally published in The Tan Sheet
Executive Summary
Unlike other OTC deals J&J made since McNeil Consumer Healthcare’s quality-control problems led to widespread recalls and a consent decree with FDA, the firm is not divesting the digestive health lines. Infirst will manufacture and market the products in the U.S. for an undisclosed period before the brands return to McNeil.
You may also be interested in...
Infirst Extends Mylanta Brand With Nighttime Product, Chewable Tablets
Infirst changes the Mylanta Maximum Strength lemon-mint liquid with a "smoother, creamier formulation" and adds a vanilla caramel-flavored version and another liquid product, Mylanta Tonight, featuring a honey chamomile flavor. Also new are Mylanta Gas Minis chewable anti-gas tablets.
Infirst Extends Mylanta Brand With Nighttime Product, Chewable Tablets
Infirst changes the Mylanta Maximum Strength lemon-mint liquid with a "smoother, creamier formulation" and adds a vanilla caramel-flavored version and another liquid product, Mylanta Tonight, featuring a honey chamomile flavor. Also new are Mylanta Gas Minis chewable anti-gas tablets.
Infirst Later Than Expected With Lipid-Format Ibuprofen, But On Time In Business Plan
The London firm announces Unicough cough/cold product’s launch after reviewing clinical trial results, but holds off on a Flarin ibuprofen launch until completing a trial. “We’re very, very pleased with this, although originally we wanted to be there slightly earlier,” says CEO Manfred Scheske.